Caricamento...
Real‐world experience of carfilzomib‐associated cardiovascular adverse events: SEER‐Medicare data set analysis
Carfilzomib was approved for the treatment of multiple myeloma in 2012 and since then there have been concerns for cardiovascular toxicity from its use. With this study, we aim to further study the hazards and underlying risk factors for cardiovascular adverse events associated with carfilzomib. Thi...
Salvato in:
| Pubblicato in: | Cancer Med |
|---|---|
| Autori principali: | , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7826471/ https://ncbi.nlm.nih.gov/pubmed/33169938 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3568 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|